Table 4 Activity and efficacy according to KRAS genotype (intent-to-treat analysis)
ORR (%) | PFS (m) range | OS (m) range | |
|---|---|---|---|
KRAS wild-type plus other than c.35 G>A KRAS mutant (44 pts) | 81 (CI ± 12) | 13 | 34 |
1+-69+ | 1+-69+ | ||
KRAS wild-type (30 pts) | 90 (CI ± 11) | 14 | 38 |
1+-69+ | 1+-69+ | ||
KRAS wild-type/BRAF wild-type (18 pts) | 83 (CI ± 14) | 13 | 31 |
4-44 | 8-66+ | ||
other than c.35 G>A KRAS mutant (13 pts) | 61 (CI ± 30) | 12 | 39 |
3-37 | 8-59+ | ||
c.35 G>A KRAS mutant (14 pts) | 71 (CI ± 26) | 9 | 14 |
1+-60+ | 1+-60+ | ||
c.35 G>T KRAS mutant (7 pts) | 57 (CI ± 40) | 12 | 21 |
3-25 | 11-46+ |